Philip C Hoffman
Overview
Explore the profile of Philip C Hoffman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tran M, Strohbehn G, Karrison T, Rouhani S, Segal J, Shergill A, et al.
Clin Lung Cancer
. 2023 Feb;
24(3):e117-e121.
PMID: 36806414
No abstract available.
2.
3.
Gutiontov S, Turchan W, Spurr L, Rouhani S, Chervin C, Steinhardt G, et al.
Sci Rep
. 2021 Oct;
11(1):20059.
PMID: 34625620
Immune checkpoint blockade (ICB) improves outcomes in non-small cell lung cancer (NSCLC) though most patients progress. There are limited data regarding molecular predictors of progression. In particular, there is controversy...
4.
Bestvina C, Pointer K, Karrison T, Al-Hallaq H, Hoffman P, Jelinek M, et al.
J Thorac Oncol
. 2021 Sep;
17(1):130-140.
PMID: 34500113
Introduction: Previous studies have evaluated stereotactic body radiotherapy (SBRT) in oligometastatic patients with NSCLC, including multimodality treatment with anti-programmed cell death protein-1 monotherapy. Questions remain regarding the timing of SBRT...
5.
ODonnell P, Trubetskoy V, Nurhussein-Patterson A, Hall J, Nath A, Huo D, et al.
Breast Cancer Res Treat
. 2020 May;
181(3):623-633.
PMID: 32378051
Purpose: Capecitabine is important in breast cancer treatment but causes diarrhea and hand-foot syndrome (HFS), affecting adherence and quality of life. We sought to identify pharmacogenomic predictors of capecitabine toxicity...
6.
Nanda R, Stringer-Reasor E, Saha P, Kocherginsky M, Gibson J, Libao B, et al.
Springerplus
. 2016 Jul;
5(1):947.
PMID: 27386391
Purpose: Glucocorticoid receptor (GR) overexpression is associated with poor prognosis ER-negative breast cancer. GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical...
7.
Vigneswaran J, Tan Y, Murgu S, Won B, Patton K, Villaflor V, et al.
Oncotarget
. 2016 Mar;
7(14):18876-86.
PMID: 26934441
This study reviews extensive genetic analysis in advanced non-small cell lung cancer (NSCLC) patients in order to: describe how targetable mutation genes interrelate with the genes identified as variants of...
8.
Kelly K, Altorki N, Eberhardt W, OBrien M, Spigel D, Crino L, et al.
J Clin Oncol
. 2015 Sep;
33(34):4007-14.
PMID: 26324372
Purpose: Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors have proven efficacy in advanced non-small-cell lung cancer (NSCLC). We hypothesized that erlotinib would be efficacious in the adjuvant setting. Patients...
9.
Maitland M, Levine M, Lacouture M, Wroblewski K, Chung C, Gordon I, et al.
BMC Cancer
. 2014 Jan;
14:5.
PMID: 24386952
Background: Candidate predictive biomarkers for epidermal growth factor receptor inhibitors (EGFRi), skin rash and serum proteomic assays, require further qualification to improve EGFRi therapy in non-small cell lung cancer (NSCLC)....
10.
Lukas R, Nicholas M, Villaflor V, Hoffman P, Salgia R
J Neurol Res
. 2013 Mar;
2(1):1-9.
PMID: 23504695
Background: Patients with lung cancer who develop brain metastases have a poor prognosis. Those patients with progressive brain metastases tend to have a dismal prognosis. Currently, there is no standard...